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Bone disease in pediatric patients undergoing dialysis with CAPD or
CCPD. The histologic features of renal osteodystrophy and the preva-
lence of bone aluminum deposition in children receiving regular dialysis
have not been described. Forty-four pediatric patients undergoing
continuous ambulatory (CAPD) or cycling (CCPD) peritoneal dialysis
had bone biopsies and deferoxamine (DFO) infusion tests; all were
receiving oral calcitriol. Osteitis fibrosa (OF) was found in 39%, mild
lesions (M) in 25%, normal histology (NH) in 16%, aplastic lesions (AP)
in 11%, and osteomalacia (OM) in 9%. Bone surface aluminum (SA)
was present by histochemical staining in 10 out of 20 given aluminum-
containing phosphate-binding agents and in 0 of 24 treated with calcium
carbonate; y2 = 15.5, P < 0.0001. Serum biochemistries and DFO
infusion tests failed to predict bone histology, but plasma aluminum
levels were markedly elevated and bone aluminum content was highest
in patients with OM. Bone formation rate (BFR) correlated with serum
parathyroid hormone (PTH), r = 0.55, P < 0.001; BFR was inversely
related to bone aluminum content (r =
—0.42. P < 0.01). even in
patients with OF (r = —0.66, P < 0.05). All patients with SA > 30% had
normal or reduced BFR when compared to those with SA < 30%; X2 =
12.2, P < 0.005. Based on SA > 30%, six patients were classified as
aluminum-related bone disease: three OM, one AP, and two NH.
Two-thirds of pediatric patients undergiong CAPD/CCPD have persist-
ent hyperparathyroidism despite treatment with calcitriol, but alumi-
num can adversely affect BFR when SA exceeds 30% regardless of
histologic lesion or serum PTH level.
Osteitis fibrosa is the most common histologic lesion of renal
osteodystrophy both in adults and in children [1—3, 5, 6, 9, 10],
and treatment with either 25-hydroxyvitamin D or 1,25 dihy-
droxyvitamin D may control secondary hyperparathyroidism in
such patients [5, 10—121. However, one-third to one-half of
pediatric patients with chronic renal failure have osteomalacia
despite normal serum levels of 25-hydroxyvitamin D [61. Alu-
minum deposition in bone has been implicated in the pathogen-
esis of renal osteomalacia [13], but previous studies of bone
disease in uremic children have not systematically assessed the
prevalence of aluminum deposition [4—7, 9, 10]. With the
development of effective therapies for aluminum-related bone
disease [14], it is important to determine the relative contribu-
tions of secondary hyperparathyroidism and bone aluminum
accumulation to the pathogenesis of renal osteodystrophy in
children undergoing maintenance dialysis. The present study
was undertaken to characterize the histopathology of bone in
pediatric patients treated by continuous ambulatory (CAPD) or
continuous cycling (CCPD) peritoneal dialysis and to determine
the value of non-invasive biochemical measurements as predic-
tors of specific skeletal lesions.
Methods
Study protocol
Studies using quantitative histology of bone have provided
valuable information about the pathogenesis and treatment of
renal osteodystrophy in adult patients receiving long-term dial-
ysis [1—31. Only limited information is available, however,
regarding the histologic features of bone disease in children
undergoing maintenance dialysis. Previous reports contain
small numbers of patients treated by hemodialysis or by inter-
mittent peritoneal dialysis [4, 5], and they have often included
children with both moderate and advanced chronic renal failure
[4, 6, 7]. In addition, the histologic features of renal osteodys-
trophy in pediatric patients undergoing continuous peritoneal
dialysis have not been described despite substantial increases in
the use of this treatment in uremic children [8].
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All pediatric patients treated by CAPD/CCPD at the UCLA
Center for the Health Sciences who consented to undergo iliac
crest bone biopsy and a deferoxamine infusion test were
entered into the study. The investigational protocol was ap-
proved by the UCLA Human Subjects Protection Committee,
and informed consent was obtained from all patients and/or
their parents. Forty-four subjects, 22 females and 22 males,
among 55 to 60 patients receiving CAPD/CCPD were evaluated;
13 were treated by CAPD and 31 by CCPD. The mean age of
patients was 11.8 5.8 years, and the duration of peritoneal
dialysis was 22.2 14.9 months with a range of five to 59
months. Twenty-four patients had congenital renal disease, and
twenty had acquired renal disease. Four subjects had under-
gone subtotal parathyroidectomy three to five years before
entry into the study.
At the time of bone biopsy, 20 patients were receiving
aluminum hydroxide as a phosphate-binding agent; the duration
of therapy with aluminum hydroxide was 10 toSS months, and
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the daily dose ranged from 70 to 280 mg/kg. Calcium carbonate
was given as a phosphate-binding agent in 24 patients; II of the
24 never received aluminum hydroxide whereas 13 had previ-
ously been treated with aluminum hydroxide, These 13 patients
received calcium carbonate for 16.8 6.7 months prior to
study; therefore, they were included in the calcium carbonate
group. The daily dose of calcium carbonate ranged from 62 to
230 mg/kg [15]. All patients received oral calcitriol at dosages
sufficient to maintain serum calcium levels between 10.5 and
11.0 mg/dl [161. The concentration of aluminum in various lots
of peritoneal dialysate was monitored throughout the study;
these were consistently below 5 gig/liter.
The deferoxamine infusion test was done as described else-
where [17]. Deferoxamine (DFO), 40 mg/kg, was given by slow
intravenous infusion over a two hour period. After the start of
the DFO infusion, the peritoneal cavity was emptied for either
six or 10 hours in patients treated by CAPD and CCPD,
respectively. Regular dialysate exchanges were then resumed.
Plasma samples for aluminum determinations were obtained
before and 24 hours after the start of the infusion of DFO.
Bone biopsies were taken from the iliac crest using a modified
Bordier trephine at a site two cm posterior and two cm inferior
to the anterior iliac spine with the patient supine [181. All
biopsies were done within four weeks of the DFO infusion test.
Prior to biopsy, all patients were given tetracycline, 10
mg/kg/day, on two occasions separated by an interval of 17 days
to achieve tetracycline labeling of bone. For children under
eight years of age, each course of tetracycline was limited to
two days and the total dose did not exceed 40 mg/kg [19]. For
children older than eight years of age, three days of tetracycline
were given for each label. A separate sample of trabecular bone
was obtained using a Jamshidi needle for determinations of total
bone aluminum content. Serum samples for the measurement of
calcium, phosphorus, alkaline phosphatase and immunoreac-
tive parathyroid hormone (iPTH) levels were obtained at the
time of bone biopsy.
Bone histology
Biopsy specimens were prepared for quantitative histological
assessment as previously described [20]. Five jzm sections of
non-decalcifled bone were stained by the modified Goldner
technique for light microscopic examination and by the aurine
tricarboxylic acid method for the histochemical detection of
bone surface aluminum [20, 211. Ten tm sections were mounted
unstained in 10% glycerol and examined by fluorescence mi-
croscopy for the evaluation of tetracycline labels [20]. All
measurements of length, width and area were done using a
digitizer interfaced with a microcomputer, and the results
represent two dimensional values. Image projection to the
surface of the digitizer tablet was achieved using a projection
prism and drawing tube attached to a Leitz Dialux microscope
with epifluorescent illuminator (Leitz, Wetzlar, FRG) [201.
The following histologic variables were determined for
trabecular bone: 1) total bone area (%)—the area of trabecular
bone, including both mineralized bone and unmineralized bone
matrix (osteoid), expressed as a percentage of the total tissue
area; 2) osteoid area (%)—the area of unmineralized bone
matrix expressed as a percentage of the total bone area; 3)
osteoid surface (%)—the percentage of trabecular bone surfaces
covered by osteoid seams; 4) resorption surface (%)—the
percentage of trabecular bone surfaces that exhibited charac-
teristic scalloped margins along bony trabeculae; 5) osteoid
seam width (ttni)—the mean width of surface osteoid seams and
obtained by dividing the measured osteoid area, in mm2, by the
length, in mm, of trabecular surface covered by osteoid; 6)
double tetracycline-labeled surface (%)—the percentage of
trabecular bone surfaces that exhibited double bands of tetra-
cycline fluorescence; and 7) double labeled osteoid surface
(%)—the percentage of osteoid surfaces that assumed a double
tetracycline label [201. Histochemical measurements of the
bone aluminum content were expressed as the percentage of
trabecular surfaces that stained positive for aluminum [20, 21].
The rates of mineralized bone apposition were determined
from measurements of the width of separation of double tetra-
cycline labels divided by the time interval between the admin-
istration of the two labels; the results are expressed in ELm/day
[20]. No correction was made for obliquity of the plane of tissue
section. Bone formation rates were calculated as described
previously, and these values represent the area of mineralized
hone formed per day [201. Results are expressed per unit area of
existing trabecular bone (BFRh) and per unit area of tissue
(BFR), both in .tm2/mm2/day.
Normal values for bone histology and tetracycline-based
measurements of bone formation were obtained from iliac crest
bone biopsies done in ten children, ages 2.5 to 17 years, (mean
11.9 5.0 yr), who had undergone orthopedic surgery for
conditions not associated with metabolic bone disease (Results,
Tables 1 and 2). None had received corticosteroids, anticon-
vulsant medications, or vitamin D preparations, and none were
diabetic. All were physically active according to their ages, and
none had a history of renal disease.
On the basis of the results obtained in normal children,
patients were classified according to the following criteria:
osteitis flbrosa—osteoid area <12%, presence of fibrosis and
' 2BFRI >97 tim/mm /day; mild lesion—osteoid area <12%, no
tissue fibrosis and BFR, >613 ism2/mm2/day; normal histol-
ogy—no fibrosis, osteoid volume <12%, and BFR, >97 but
<613 .m2/mm2/day; aplastic bone—osteoid area <12%, no
fibrosis and BFR, <97 m2/mm2/day; osteomalacia—osteoid
area >12%, no fibrosis and BFR <97 m2/mm2/day; and mixed
lesion—osteoid area >12%, fibrosis present, and BFRI <97
m2/mm2/day.
Biochernistries
Calcium, phosphorus and alkaline phosphatase levels in
serum were determined using a Technicon Autoanalyzer LI.
Serum iPTH was measured by radioimmunoassay using an
antiserum (Ch 9) that reacts with the intact and carboxy-
terminal regions of the PTH molecule [22]. Serum alkaline
phosphatase values were corrected for age and sex according to
the data of Cherian and Hill [23], and the results for individual
patients were expressed as the percentage of the median value
for normals as previously reported [16]. Plasma aluminum
levels were measured by flameless atomic absorption spec-
trophotometry using a graphite furnace [24], and chemical
determinations of the aluminum content of bone were done
after ashing and extraction with EDTA for 24 hours as previ-
ously described [24].
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Table 1. Histomorphometry and aluminum content of bone in children on CAPD/CCPD
Histologic groups
Table 2. Tetracycline-based bone dynamics in children on CAPD/CCPD'
Histologic groups
Osteitis
11 brosa
[OF]
N = 17
Normal
histology
[NHI
N= 7
Aplastic Osteomalacic
[API [OMIN=5 N=4
0.4 0.6°c 0.1 0.2"'
Normal values
Mean SD
N — 10
4.0 3.0
Statistical analysis
All results are expressed as the mean standard deviation.
Statistical analysis of the data was done using the t-test for
unpaired samples, one way analysis of variance with contrasts,
linear regression analysis, and chi-square analysis [251. The
rank-sum test was used for comparisons between groups with
unequal within-groups variances [25].
Osteitis Normal
fibrosa Mild histology Aplastic Osteomalacic
[OF] [MI [NH] [API [OM]
N= 17 N= II N=7 N=5 N=4
Normal values
Mean SD
N = 10
21.3 3.2
2.6 1.5
18.1 6.1
7.1 2.3
2.3 0.9
0
Range
14.6—25.7
1.1—5.8
10.2—29.9
4.1—11.3
1.1—3.5
Bone volume % 31.8 8.8 29.4 5.7 26.6 5.7 27.9 11.5 30.7 10.1
Osteoid area 6.0 4.1 6.4 3.4 4.9 2.7 3.1 3.4 20.3 9.8"
Osteoid surface % 43.1 17.7 41.4 14.8 36.6 l7.6 18.9 15.6 63.2 113dc
Osteoid seam width p.m 10.1 3.8 9.4 2.6 8.5 2.3 8.2 3.9 24.9 ' 15.3"""'
Resorption surface % 7.0 3.1"' 4.1 1.7 2.9 1.4 2.3 1.2 1.6 1.1
Surface stainable Al Ye 3.2 8.9 2.2 5.2 12.8 23.4 12.1 27.2 58.5 4l.4C
N" 2/17 2/lI 2/7 1/5 3/4
Bone Al mg/kg/dry ni 38.5 29.6 13.5 21.9 51.7 90.7 70.6 81.9 123.7 l09.75c1
Parathyroidectomy N 2 I — — I
Probabilities determined by analysis of variance except as indicated
"P < 0.01 OM vs. OF
P < 0.01 OM vs. M
' P < 0.01 OM vs. NH
P < 0.01 OM vs. AP
P < 0.05 NH vs. AP
" P < 0.01 OF vs. M
h P < 0.01 OF vs. NH
P < 0.01 OF vs. AP
P < 0.01 OF vs. OM
Refers to number of cases with a positive surface stainable aluminum
P < 0.05 OM vs. NH
2.4 1.2 0—4
Mild
[M]
N = Ii
60.3 27.1"'-
1.3 0.2
4718 1519'-
14.5 23d 4.8 2.3
40.2 23.3" 17.3 14.9
1.4 0.3 1.2 0.4
4310 1680' 1340 890
1246 510d 319 155
3.7 6.3'-'
0.6 09'-"
140 193
Range
0.3—8.5
0.2 0.3"'
0.2 04hai,
38 75"
24.5 18.9
1.2 0.2
1197 762
35 9 18h,p
1.8—58.3
l.0-l.5
484—2782
Double tetracycline labelled 22.5 75hc
surface Ye hone snrtace
Osteoblastic osteoid Ye osicoid
Mineral apposition rate p.m/dos
Bone formation" rate—B FR
p..m2/mm2/dav
Bone formation" rate—BFR, 1502 626'-
pjn2/mm2/dav
Mineralization0 lag time days 16 10'- 27 34(1 83 79 61 24 26 151'
0 Probabilities determined by analysis of variance except as indicated
"P < 0.01 OF vs. M
P < 0.01 OF vs. NH
d P < 0.01 M vs. NH
P < 0.01 AP vs. OF
l P < 0.01 AP vs. M
"P < 0.01 AP vs. NI-I, non-paired (-test
P < 0.01 OM vs. OF
P < 0.01 OM vs. M
P < 0.01 OM vs. NH, non-paired i-test
k p < 0.05 OM vs. NH, non-paired i-test
'I' < 0.01 AP vs. NH
P < 0.01 OM vs. NH
" P < 0.01 AP vs. NH, non-paired (-test
0 analysis done excluding OM
1' does not include 3 patients with values approaching infinity
" statistical differences reflect criteria for classification (Methods)
255 171 97—613
36 36 5—104
Results
Of the 44 patients studied, 17 had osteitis fibrosa, 11 had mild
lesions, seven had normal findings on bone biopsy, five had
aplastic lesions, and four had osteomalacia (Tables I and 2).
None had mixed renal osteodystrophy. Patients in each group
were similar with respect to age, duration of peritoneal dialysis
and end-stage renal disease, the number with congenital and
acquired renal diseases, and the number that had undergone
previous renal transplantation or parathyroidectomy (Tables I
and 3).
Serum calcium, phosphorus and immunoreactive parathyroid
hormone (iPTH) levels did not differ among groups, although
the mean values for serum iPTH were two to three times higher
in patients with osteitis fibrosa than in those with other his-
tologic lesions (Table 3). Serum alkaline phosphatase values,
both uncorrected and corrected, were highest in patients with
osteitis fibrosa and osteomalacia, but the results did not differ
between the two groups. In patients with mild and aplastic
lesions, alkaline phosphatase levels were not different from the
values determined in non-uremic subjects or patients with
normal bone formation and histology (Table 3). The daily dose
of calcitriol was higher in patients with osteitis fibrosa than in
each of the other four groups (Table 3).
In patients with osteitis fibrosa, resorption surface was
greater than in each of the other four groups, and the rate of
bone formation was approximately 2.5 times the upper limit of
normal (Tables 1 and 2). Osteoid area was between 10% and
12% in two biopsies, but tetracycline-based measurements did
not confirm a defect in mineralization in either patient. In two
other patients with osteitis fibrosa, the histochemical stain for
aluminum was positive, but the values were below 30%. In both
cases, the rate of bone formation was increased and the
mineralization lag time was normal.
In the eleven patients with mild lesions, percent resorption
surface was lower than in patients with osteitis fibrosa, and the
values did not differ from those determined in non-uremic
children or patients with normal bone biopsy findings (Table 1).
Osteoid surface and osteoid area were not different in patients
with mild and fibrotic lesions, and bone formation was elevated
to a similar degree in each group (Tables 1 and 2). Two cases
with mild renal osteodystrophy had histochemical evidence of
aluminum deposition in bone with values of 5.9% and 15.9%;
bone aluminum contents were 69 and 42 mg/kg dry weight,
respectively, and these were the highest levels among patients
with mild lesions.
Bone formation was within the normal range and the his-
tologic findings were predominantly normal in seven patients
(Tables I and 2). Two of these patients had deposits of
aluminum at 59.3% and 30.3% of trabecular surfaces, and the
corresponding bone aluminum levels were 231 and 61 mg/kg dry
weight.
Five patients had aplastic lesions, but the values for osteoid
area, osteoid seam width, and percent resorption surface did
not differ from those in non-uremic subjects or dialysis patients
with normal bone biopsy findings (Table I). In contrast, the
percent osteoid surface and the extent of double tetracycline-
labeled surface were lower than in the seven dialysis patients
with normal bone histology and bone formation (Tables I and
2). No double tetracycline labels were seen in three patients,
and bone formation could not be measured. One patient with
the aplastic lesion had 60.7% surface stainable aluminum and a
chemical bone aluminum level of 165 mg/kg dry weight. The
other four cases had no surface stainable aluminum, and bone
aluminum levels were below 30 mg/kg dry weight.
Osteomalacia was confirmed in four patients; all exhibited
marked increases in osteoid area and osteoid seam width with
diminished tetracycline uptake into bone (Tables I and 2). Bone
formation was measurable in only one of the four patients, and
this value was substantially below the lower limit of normal; in
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Table 3. Serum biochemistries and calcitriol dosages according to the type of bone disease in children on CAPD/CCPD
Normal
histology Aplastic Osteomalacic
[NH] [AP] [OM]N=7 N5 N=4
Osteitis
fibrosa [OF]
N—17
12.8 5.5
Mild
[M]
N—Il
Age yrs 10.3 6.2 11.9 7.0 11.1 7.7 12.1 4.2
CAPD/CCPD months 28 14 25 17 14 7 12 7 21 II
Calcium mg/dl 9.6 0.7 10.0 1.0 9.9 0.6 10.2 0.9 10.6 1.2
Phosphorus mgldl 6.4 1.2 6.0 1.4 5.2 1.5 7.2 1.9 5.9 + 2,5
Alk. phosphatase
Uncorrected lU/liter 424 ÷ 357ub 174 84 174 144 95 12 308 88
Corrected % 274 170ab 108 53 99 58 62 49 265 2851
iPTH pJEq/ml
Baseline Al pg/liter
493 505
30 18
231 149
31 23
224 238
18 + 15
148 11660 52
248 + 77
470 848cfgh
AL increment after DFO pg/liter 148 128 85 123 119 185 345 490 495 456
Calcitriol dose ng/kg 33 27' 17 9 II 9 9 7 10 5
a < 0.01 OF vs. M
b P < 0.01 OF vs. NH
P < 0.01 OM vs. NH
d p < 0.01 OM vs. AP
< 0.01 OM vs. OF
P < 0.05 OM vs. M
P < 0.01 OM vs. NH
h p < 0.01 OM vs. AP
'P < 0.01 OF vs. AP
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Table 4. Bone formation and bone surface stainable aluminum in 44
patients receiving CAPD/CCPD
Surface stainable aluminum0
<30% 30—50% >50% Totals
Bone formation rate
Low
Normalb
High
Totals
5
S
28
38
(86.4%)
0
I
0
I
(2.3%)
4
1
0
5
(11.4%)
9 (20.5%)
7 (15.9%)
28 (63.6%)
44(100%)
Chi-square = 19.0; Degrees of freedom = 4; P < 0.005.
The percentage of trabecular bone surfaces positive for aluminum
b Bone formation per unit area of tissue; normal range: 97—613
zm2/mm2/day
the other three, no tetracycline uptake was observed. Three of
four patients had histochemical evidence of skeletal aluminum
deposition; all values exceeded 50%, and the bone aluminum
content was 161 99 mg/kg dry weight. The bone aluminum
content was 13 mg/kg dry weight and the histochernical stain for
aluminum was negative in the remaining patient with osteoma-
lacia.
Serum iPTH levels in the 44 patients correlated with percent
resorption surface, r = 0,61, P < 0.001. Bone formation was
also directly related to the serum level of iPTH when all patients
were considered, r = 0.55, P < 0.001. This relationship was
stronger when only patients with mild and fibrotic lesions were
evaluated, r = 0.61, P < 0.001, and it was greatest when the
analysis was confined to the 17 patients with osteitis fibrosa, r =
0.84, P < 0.001, Bone formation was inversely related to the
bone aluminum content, whether determined by chemical, r
—0.42, P < 0.01, or by histochemical methods, r =
—0.46, P <
0.01. Even in patients with osteitis fibrosa, the rate of bone
formation was inversely related to the total aluminum content
of bone, r =
—0.66, P < 0.05.
There was a direct relationship between the chemical mea-
surement of bone aluminum content and percent surface stain-
able aluminum, r = 0.86, P < 0.001, and patients with osteo-
malacia had the highest levels of aluminum in bone by chemical
determinations. Although the histochemical measurements of
stainable bone aluminum varied among groups, the distribution
of cases with surface stainable aluminum greater than 30% was
substantially different (Table 4). None of the 28 patients with
bone formation rates above the normal range had bone alumi-
num levels in excess of 30% by histochemical staining. In
contrast, four of the nine patients with subnormal rates of bone
formation had more than 30% surface stainable aluminum, x2 =
14,0, df = 1,P < 0.005, and all patients with values for stainable
aluminum above 30% had normal or reduced bone formation, x2
= 12.2, df = 4, P < 0.005. Serum calcium concentrations, basal
plasma aluminum levels and the increment in plasma aluminum
after DFO were higher, whereas serum PTH levels were lower
in patients with more than 30% surface stainable aluminum
(Table 5). Patients with more than 30% surface stainable
aluminum had higher values for osteoid area and mineralization
lag time, but resorption surface, tetracycline-labeled surface
and bone formation were lower when compared to those with
less than 30% surface stainable aluminum (Table 5).
Table 5. Characteristics of 44 pediatric patients on CAPD/CCPD with
values for surface stainable aluminum <30% or >30%
<30%
N=38
>30%
N=6 Pvalue0
Ageyrs 11.4 5.6 14.7 7.2 NS
Duration of CAPD/CCPD 22.3 15.6 20.5 9.3 NS
months
Serum calcium mg/cl! 9.8 0.8 10.6 0.9 <0.05
Serum iPTH pJEq/m! 352 376 146 122 <0.05
Plasma Al p.g/liter 28 20 344 685 <0.05
Increment in plasma Al 140 119 546 399 <0.05
after DFO ag/liIer
Bone Al content mg/kg 24 27 157 83 <0.01
thy WI
Osteoid area % 6.1 6.0 12.3 4.2 <0.05
Resorption surface % 5.0 3.0 2.3 1.1 <0.01
Double tetracycline 15.0 10.2 0.6 1.2 <0.001
labeled surface %
Bone formation rater' 1083 744 90 137 <0.001
i.m2/mm2/day
Mineralization lag time 26 30 975 1422C <0,05d
days
0 Probabilities estimated by the i-test for unpaired samples except as
indicated
b Expressed per unit area of bone tissue
Results do not include 4 patients with values approaching infinity
d Probability estimated using the Wilcoxon rank-sum test
Basal plasma aluminum levels correlated with the chemical
measurements of bone aluminum content, r = 0.59, P < 0.001,
and plasma aluminum concentrations were substantially higher
in patients with osteomalacia (Table 3). For the entire study
population, the increment in plasma aluminum after a single
infusion of DFO correlated with the degree of aluminum accu-
mulation in bone as assessed by chemical, r = 0.73, P < 0.001,
and histochemical methods, r = 0.73, P <0.001. Despite these
findings, the increase in plasma aluminum following DFO
infusions did not differ among the five groups (Table 3).
The bone aluminum content was higher in the 20 patients
treated with aluminum hydroxide than in the 24 patients given
calcium carbonate as a phosphate-binding agent (Table 6), and
the finding of surface stainable aluminum was confined to
patients who had received aluminum orally, = 15.5, df = 1,
P <0.0001. The rise in plasma aluminum after DFO infusions
was also greater in patients who had ingested aluminum-
containing antacids (Table 6). Serum iPTH levels were lower in
this group despite serum calcium values that did not differ from
those in patients receiving calcium carbonate. Conversely, the
uncorrected values for serum alkaline phosphatase were higher
in aluminum-treated patients (Table 6). The mean age of pa-
tients was similar in each group, but the duration of peritoneal
dialysis was greater for those receiving aluminum gels.
Discussion
The distribution of histologic lesions of renal osteodystrophy
and the predominance of secondary hyperparathyroidism in the
current study is similar to that reported in adults receiving
regular dialysis and in some studies of pediatric hemodialysis
patients [1—3, 9, 101, but it differs substantially from other
observations in uremic children [4, 61. In the latter reports,
osteomalacia and mixed lesions were prevalent findings. The
use of calcitriol in the current study may account, in part, for
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Table 6. Characteristics of 44 pediatric patients on CAPD/CCPD
receiving calcium carbonate or aluminum containing gels, as
phosphate-binding agents
Calciuma AluminumbN 24 N = 20 Pvaluea
Bone aluminum content 7.8 8.5 87.8 69.8 <0.001
mg/kg dry wt
No. with surface stainable Al 0/24 10/20 <O.000l
Increment in plasma Al after 44.5 34.9 325 299 <0.01
DFO jj.g/liter
Plasma Al ig/liter 22 15 141 400 <0.005
Serum calcium mg/dl 9.8 0.9 10.2 0.9 NS
Serum alkaline phosphatase
Uncorrected lU/liter 186 112 402 358 <0.05
Corrected % 146 129 235 192 NS
Serum iPTI-I pJEq/ml 387 403 186 132 <0.05
Age yrs 11.2 6.2 12.5 5.7 NS
Duration of CAPD/CCPD 16.7 14.4 28.5 12.0 <0.01
a Calcium carbonate
Aluminum hydroxide/aluminum carbonate
C Probabilities estimated using the t-test for unpaired samples except
as indicated
d Probability estimated by chi-square analysis
Probability estimated by rank-sum test
this difference. In addition, previous reports in pediatric pa-
tients have not consistently used double tetracycline labeling of
bone [6, 7, 9, 101 or histochemical assessments of bone alumi-
num content [4—101.
Sixty-four percent of patients in the current study demon-
strated findings of secondary hyperparathyroidism despite treat-
ment with calcitriol. The predominance of hyperparathyroid
bone disease is consistent with data previously reported from
this institution [261 and by others [27, 281. Secondary hyper-
parathyroidism is difficult to control in children receiving pen-
toneal dialysis, and doses of calcitriol sufficient to raise serum
calcium concentrations into the upper range of normal are often
necessary to lower serum iPTH levels and to ameliorate the
biochemical and roentgenographic features of osteitis fibrosa
[161.
Histochemical evidence of aluminum deposition in bone was
found in 23% of the patients, all of whom received aluminum
hydroxide. The role of aluminum in the pathogenesis of renal
osteodystrophy is a subject of continued interest. Twenty-five
to 30% of asymptomatic adult hemodialysis patients were found
to have aluminum-related bone disease 129—311, but the defini-
tion of this disorder is not yet established and diagnostic criteria
vary substantially among investigators [29—321. Dialysis pa-
tients with both osteomalacia and aplastic lesions often have
surface stainable aluminum in bone [131, and Andress et al
defined aluminum-related bone disease by the presence of
subnormal rates of bone formation and more than 25% surface
stainable aluminum [31]. Nevertheless, some dialysis patients
have aluminum accumulation in bone both by chemical and by
histochemical determinations, but lack the histologic features
and low bone formation which suggest skeletal aluminum
toxicity [2, 3, 13, 31, 331. Consequently, the pathogenic role of
aluminum in renal osteodystrophy has been questioned [34].
The data from the current cross-sectional study of pediatric
patients receiving CAPD/CCPD indicate that aluminum ad-
versely affects bone formation when values for histochemical
surface stainable aluminum exceed 30%. None of the 28 pa-
tients with high rates of bone formation due to mild or advanced
secondary hyperparathyroidism had more than 30% surface
stainable aluminum; lesser values were occasionally seen, but
24 had a negative histochemical stain for aluminum. Converse-
ly, six of 16 patients with normal or reduced rates of bone
formation had >30% surface stainable aluminum, and bone
formation varied inversely with total bone aluminum content.
This was true both for the study group and for the 17 patients
with osteitis fibrosa. Thus, aluminum deposition in bone may
reduce mineralized bone formation in patients with persistently
high serum levels of PTH and histologic evidence of PTH action
on bone.
Based on the finding of surface stainable aluminum >30%, six
patients from the current series were classified as aluminum-
related bone disease; three had osteomalacia, one had aplastic
bone, but two had normal bone histology and bone formation.
Although the current results are consistent with previous data
which indicate that the serum level of PTH is a major determi-
nant of bone formation in patients receiving regular dialysis [35,
36], they also suggest that aluminum accumulation in bone can
modify this relationship. Accordingly, bone formation may be
inappropriately low regardless of the histologic findings in
individual patients undergoing regular dialysis when there is
substantial aluminum deposition in bone.
As noted by others [4, 6, 7, 101, serum biochemical measure-
ments are poor predictors of bone histology in pediatric patients
undergoing maintenance dialysis. Patients with osteitis fibrosa
and osteomalacia both had increased serum levels of alkaline
phosphatase, but there were no differences between groups.
High basal plasma aluminum levels suggested substantial bone
aluminum accumulation; values were greatest in patients with
osteomalacia, but the increase in plasma aluminum after DFO
infusions failed to distinguish among histologic subgroups. Of
particular interest, serum iPTH levels were not reduced in
children with renal osteomalacia. Although serum iPTH levels
were somewhat lower in the six patients with >30% surface
stainable aluminum, the results overlapped considerably with
those for patients with <30% surface stainable aluminum.
Thus, pediatric patients may be less susceptible than adults to
the putative suppressive effect of aluminum on PTH secretion
[37].
Several studies in adult patients undergoing maintenance
dialysis suggest that low serum levels of PTH may contribute to
the development of aluminum-related bone disease, particularly
after parathyroidectomy [38—40]. However, only one of four
patients in the current study who had undergone subtotal
parathyroidectomy developed aluminum-related bone disease
despite the continued ingestion of aluminum-containing gels.
Serum 1PTH levels also did not differ among the five histologic
subgroups, and the values remained moderately elevated in all
patients with histochemical evidence of bone aluminum depo-
sition. Although these findings differ from observations using
the same radioimmunoassay for PTH in adult patients with
renal osteodystrophy [401, the data indicate that reductions in
the serum level of PTH are not a prerequisite for the develop-
ment of aluminum-related bone disease in pediatric patients
receiving CAPD/CCPD.
Aluminum-containing, phosphate-binding agents were the
apparent source of aluminum loading in the patients studied.
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Bone aluminum levels were higher in those receiving aluminum
hydroxide or aluminum carbonate, and all patients with a
positive histochemical stain for aluminum had received these
drugs. The mean serum iPTH levels were lower in patients
given aluminum, but individual values did not distinguish
aluminum-treated patients from those managed with calcium
carbonate. Although use of calcium carbonate as a phosphate-
binding agent reduces the potential for enteral aluminum load-
ing in patients undergoing maintenance dialysis 115, 411, the
long-term efficacy and safety of this agent has yet to be
established [42].
In summary, renal osteodystrophy in pediatric patients un-
dergoing CAPD/CCPD is a heterogeneous disorder not unlike
the situation described in adults. Hyperparathyroidism remains
the predominant skeletal lesion in dialyzed children despite the
use of oral calcitriol. Aluminum accumulation in bone second-
ary to the use of aluminum containing gels is a prominent
finding in most, but not all, cases of osteomalacia, and it may
adversely affect bone formation in pediatric patients with other
histologic lesions of renal osteodystrophy.
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